EDITNASDAQEditas Medicine Inc

EDIT price activity

Last Price

Change (24hr)

USD (%)

Volume

Volume (4w avg)

Previous Close

N/A

Last Trade

EDIT price performance

12.6%

-22.53%

41.71%

YTD

16.67%

EDIT price fundamentals

N/A

Shares Issued

N/A

Earnings Per Share (EPS)

N/A

Dividends Per Share (DPS)

N/A

P/E Ratio

Price market cap

Market cap

N/A

US-NASDAQ rank

N/A

Sector Rank

N/A

EDIT details

View company profile

View company website

View US-NASDAQ Official Page

EDIT Market Signals

More ways to discover

Browse United States news Discover NASDAQ signals Browse all NASDAQ stocks

Editas Medicine Inc (US-NASDAQ: EDIT)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Price: $2.91

Sector: Healthcare — Biotechnology